CTLA4 and neoplasm: We tested the efficacy of HBI-8000 in combination with anti-PD1, anti-PD-L1 or anti-CTLA4 monoclonal antibodies in multiple preclinical tumor models (e.g. MC38, CT26, and A20) to investigate its activity in tumor immunity.